4D Molecular Therapeutics Inc (NAS:FDMT)
$ 25.15 0 (0%) Market Cap: 1.30 Bil Enterprise Value: 788.60 Mil PE Ratio: 0 PB Ratio: 2.14 GF Score: 57/100

4D Molecular Therapeutics Inc at Chardan Genetic Medicines Conference Transcript

Oct 02, 2023 / 06:30PM GMT
Release Date Price: $11.81 (-7.23%)
Geulah Livshits
Chardan Capital Markets LLC - Analyst

It is now my pleasure to introduce our next guests, Uneek Mehra, Chief Financial and Business Officer; and Julian Pei, Head of IR and Corporate Finance at 4D Molecular Therapeutics. The format for this session is a fireside chat, which we might open to audience Q&A at the end if there's time. And Uneek will also be participating in our next-gen AAV panel at 3:00.

Thank you for joining us today.

Questions & Answers

Geulah Livshits
Chardan Capital Markets LLC - Analyst

To begin with, can you give us a high-level overview of 4D Molecular and its AAV platform, and also talk about key catalysts for the year? Either of you can jump in on this.

Uneek Mehra
4D Molecular Therapeutics, Inc. - Chief Financial and Business Officer

Yeah, sure. Good afternoon and thank you for having us. It's an exciting conference. So 4D Molecular Therapeutics. It's an exciting stage in time for the platform. Our mission is to continue to unlock the full potential

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot